

Clinical trials of semaglutide

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
semaglutide vs placebo			
SUSTAIN 6 , 2016 [NCT01720446] n=1648/1649 follow-up: 2.1 y (median)	once-weekly semaglutide (0.5 mg or 1.0 mg) versus placebo	patients with type 2 diabetes who were on a standardcare regimen	Parallel groups double-blind 20 countries

More details and results :

- glucose lowering for cardiovascular prevention for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q576>
- glucose lowering for cardiovascular prevention for diabetes type 2 in meta-regression at <http://www.trialresultscenter.org/go-Q692>

References

SUSTAIN 6, 2016:

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jdar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbll T Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2016 Sep 15; [27633186] [10.1056/NEJMoa1607141](https://doi.org/10.1056/NEJMoa1607141)